TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Artiva Biotherapeutics (NASDAQ: ARTV).The analyst commented, "The Phase I/Ib ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE